The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Divergent CSF alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy
Open accessAbstract
BACKGROUND: Elevated CSF τ is considered a biomarker of neuronal injury in newly developed Alzheimer's disease (AD) and mild cognitive impairment (MCI) criteria. However, previous studies have failed to detect alterations of τ species in other primary tauopathies. We assessed CSF τ protein abnormalities in AD, a tauopathy with prominent Aβ pathology, and progressive supranuclear palsy (PSP), a primary tauopathy characterised by deposition of four microtubule-binding repeat (4R) τ with minimal Aβ pathology. METHODS: 26 normal control (NC), 37 AD, and 24 patients with PSP participated in the study. AD and PSP were matched for severity using the clinical dementia rating sum of boxes (CDR-sb) scores. The INNO BIA AlzBio3 multiplex immunoassay was used to measure CSF Aβ, total τ, and ptau181. Additional, novel ELISAs targeting different N-terminal and central τ epitopes were developed to examine CSF τ components and to investigate interactions between diagnostic group, demographics and genetic variables. RESULTS: PSP had lower CSF N-terminal and C-terminal τ concentrations than NC and AD measured with the novel τ ELISAs and the standard AlzBio3 τ and ptau assays. AD had higher total τ and ptau levels than NC and PSP. There was a gender by diagnosis interaction in AD and PSP for most τ species, with lower concentrations for male compared to female patients. CONCLUSIONS: CSF τ fragment concentrations are different in PSP compared with AD despite the presence of severe τ pathology and neuronal injury in both disorders. CSF τ concentration likely reflects multiple factors in addition to the degree of neuronal injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF tau levels are not increased in non-AD tauopathies57–60, suggesting that extracellular tau is not a primary target in these conditions.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [60]
Experimental — accuracy not yet measuredIn the citing paper
“CSF tau levels are not increased in non-AD tauopathies57–60, suggesting that extracellular tau is not a primary target in these conditions.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Wechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,680
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071
Delis-Kaplan Executive Function System
Delis, D. C., Kaplan, E., & Kramer, J. H. (2012) · PsycTESTS Dataset · doi:10.1037/t15082-000 · Cited by 2,683
Self-citationLitvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Cited by
Sorted by citations
Items 101–140 of 140
Molecular profiling in Parkinsonian syndromes: CSF biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.002 · Cited by 5
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders
Cuina, M. L., & Meissner, W. G. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.010 · Cited by 4
Episodic memory in progressive supranuclear palsy: a neuropsychological and neuroimaging study
Macedo, A. C., Caramelli, P., Resende, E. D. P. F., Mariano, L. I., Tumas, V., Teixeira, A. L., Camargos, S., Cardoso, F., & de Souza, L. C. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06160-2 · Cited by 3
Machine and Deep Learning Algorithms and Applications
Shanthamallu, U. S., & Spanias, A. (2021) · Synthesis lectures on signal processing · doi:10.2200/s01135ed1v01y202109spr022 · Cited by 3
Dilcher, R., Malpas, C. B., O’Brien, W. T., McDonald, S. J., Despott, C., Bertram, K., Pase, M. P., Law, M., O'Brien, T. J., & Vivash, L. E. (2024) · medRxiv · doi:10.1101/2024.10.14.24315486 · Cited by 3
Precipitous Deterioration of Motor Function, Cognition, and Behavior
Fernández-Fournier, M., Perry, D. C., Tartaglia, M. C., May, M. G. D., Boxer, A. L., Coppola, G., Christine, C. W., Huang, E. J., Seeley, W. W., Miller, B. L., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6159 · Cited by 2
Self-citationFluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 2
Why delay in effective treatment for Alzheimer's disease and related conditions
Iqbal, K., Liu, F., Gong, C., Dai, C., & Hu, W. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.08.002 · Cited by 1
Bonomo, R., Elia, A. E., Cilia, R., Romito, L. M., Andreasi, N. G., Devigili, G., Bonvegna, S., Straccia, G., Garavaglia, B., Panteghini, C., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.04.005 · Cited by 1
Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy
Dilcher, R., Malpas, C. B., McDonald, S. J., O'Brien, W., Despott, C., Bertram, K., Pase, M. P., Frontzkowski, L. K., Law, M., O'Brien, T. J., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70327 · Cited by 1
Plasma tau-species-positive neuron-derived extracellular vesicles in progressive supranuclear palsy
Zheng, Y., Cai, H., Kou, W., Liu, G., Wang, Y., Bai, J., Piao, Y. S., Liu, X., Zhu, X., Zhang, J., et al. (2026) · Brain · doi:10.1093/brain/awag091 · Cited by 1
Progressieve supranucleaire parese
van Domburg, P. (2016) · Neuropraxis · doi:10.1007/s12474-016-0117-4 · Cited by 1
Break and accelerator—The mechanics of Tau (and amyloid) toxicity
Cruz, E., Nisbet, R. M., & Götz, J. (2023) · Cytoskeleton · doi:10.1002/cm.21781 · Cited by 1
Assessment and staging of A/T/N with a single dynamic [ 18 F]PI-2620 recordingPreprint
Gnörich, J. S., Kusche‐Palenga, J., Kling, A., Dehsarvi, A., Bronte, A., Frontzkowski, L. K., Zatcepin, A., Zaganjori, M., Schöberl, F., Roemer, S. N., et al. (2025) · medRxiv · doi:10.1101/2025.01.14.25320240 · Cited by 1
Progressive supranuclear palsy finally has a clinically measureable abnormality
Halliday, G. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308567
Update on the Diagnosis and Management of Progressive Supranuclear Palsy
Garrido, A., Vilas, D., & TOLOSA, E. S. (2016) · Current Geriatrics Reports · doi:10.1007/s13670-016-0172-y
Tau proteolysis mechanisms and relevance for tauopathies
Quinn, J. P. (2019) · Research Explorer (The University of Manchester)
Fokus atypische Parkinsonsyndrome: Teil 2 – Progressive supranukleäre Blickparese
Jacksch, C., Paschen, S., & Berg, D. (2023) · DGNeurologie · doi:10.1007/s42451-023-00590-8
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen‐Plotkin, A. S., Rosenthal, L. S., Dawson, T. M., Na, C. H., & Pantelyat, A. Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.05.561075
Astrocytic tau inclusions lead to microglial abnormalities, but leave neuronal networks intactPreprint
Vogels, T., Vargová, G., & Hromádka, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.28.577642
Skin Biomarkers of Neurodegenerative Diseases
Reilly-Jankowiak, L., Bargar, C., Bunn, D., & Chen, S. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-66513-4_6
Additional file 6 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751392
Additional file 5 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751389
Additional file 3 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751383
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen-Plotkin, A., Rosenthal, L. S., Dawson, T. M., Na, C., & Pantelyat, A. Y. (2024) · Figshare · doi:10.6084/m9.figshare.27129465
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen-Plotkin, A., Rosenthal, L. S., Dawson, T. M., Na, C., & Pantelyat, A. Y. (2024) · Figshare · doi:10.6084/m9.figshare.27129456
Additional file 8 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751398
Additional file 1 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26333190
Additional file 7 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751395
Additional file 2 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26333445
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen-Plotkin, A., Rosenthal, L. S., Dawson, T. M., Na, C., & Pantelyat, A. Y. (2024) · Figshare · doi:10.6084/m9.figshare.27129459
Cicognola, C., Hansson, O., Scheltens, P., Kvartsberg, H., Zetterberg, H., Teunissen, C. E., & Blennow, K. (2021) · Figshare · doi:10.6084/m9.figshare.13787431
Additional file 4 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751386
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen-Plotkin, A., Rosenthal, L. S., Dawson, T. M., Na, C., & Pantelyat, A. Y. (2024) · Figshare · doi:10.6084/m9.figshare.27129462
Featherby, S. J., Faulkner, E. C., Gordon, A. D., & Ettelaie, C. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01658-7
De la cellule au primate, propagation physiopathologique de la protéine Tau
Dujardin, S. (2015) · theses.fr (ABES) · doi:10.70675/5e44811dz75d4z404az8eefzbf0e3970ef63
Identification et caractérisation fonctionnelle de nouveaux sites de clivage de la protéine Tau
Derisbourg, M. J. (2015) · theses.fr (ABES) · doi:10.70675/ef5f45b0zf4e8z433fz9beaz8d2cc6de65bc
Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP
Kac, P. R., Cousins, K. A. Q., Szadziewska, A., Shaw, L. M. J., Turton, M., Deerlin, V. M. V., Harrison, P., Zetterberg, H., Wolk, D. A., McMillan, C. T., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03042-1
Yin, L., Ren, R., Leo, C., & Lu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108439
Gnörich, J. S., Kusche‐Palenga, J., Kling, A., Dehsarvi, A., Bronte, A., Frontzkowski, L. K., Zatcepin, A., Zaganjori, M., Schöberl, F., Roemer, S. N., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00997-3
Metadata
- Authors
- Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., Tartaglia, M. C., Miller, Z., Coppola, G., Ahlijanian, M., Soares, H., Kramer, J. H., Rabinovici, G. D., Rosen, H. J., Miller, B. L., Meredith, J., & Boxer, A. L.
- Affiliations
- University of California, San Francisco (US)
- Bristol-Myers Squibb (United States) (US)
- University of California, Los Angeles (US)
- Corresponding author
- Boxer, A. L.
- ORCID
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2014-06-04
- Volume
- 86
- Issue
- 3
- Pages
- 244-250
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC4256124
- OpenAlex
- W2133759450
- Cited by
- 132
- References
- 47
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 18 · 2023: 5 · 2022: 15 · 2021: 17 · 2020: 7 · 2019: 16 · 2018: 13 · 2017: 14 · 2016: 10 · 2015: 4 · 2014: 3
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Alzheimer's Association (K23-AG031861)
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Hellman Family Foundation
- TauRx Pharmaceuticals
- Elan
- Kyowa Hakko Kirin
- H. Lundbeck A/S
- National Institutes of Health (AG19724)
- Genentech
- Avid Radiopharmaceuticals
- National Institute on Aging (AG031861, AG23501, R01AG022983, AG-19724, R01AG031278, K23AG031861, K24AG045333, R01AG038791, P01AG019724, R01AG032289, P50AG023501)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- tauopathy, Alzheimer's disease, progressive supranuclear palsy, cerebrospinal fluid tau, phosphorylated tau 181, amyloid-beta, 4R tau, sex differences, biomarkers, neuronal injury
- MeSH terms
- Aged, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Peptide Fragments, Phosphorylation, Prognosis, Reference Values, Supranuclear Palsy, Progressive, Biomarkers, Amyloid beta-Peptides, tau Proteins, Tauopathies, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
